HSPG2 could promote normal haematopoiesis in acute myeloid leukaemia patients after complete remission by repairing bone marrow endothelial progenitor cells

Abstract

	•The HSPG2 level in the BM EPCs of AML-CR patients was decreased, which was related to the reduced BM EPC function.
	•HSPG2 knockdown or Ara-C intervention reduced the HSPG2 level and led to BM EPC dysfunction, which could be restored by HSPG2 treatment in vitro.
	•HSPG2 treatment restored the BM EPC function of AML-CR patients without affecting their leukaemia cell-supporting ability.

Keywords

Acute myeloid leukemia / Complete remission / Endothelial progenitor cells / Hematopoiesis

References

[1] OhIH, KwonKR. Concise review: multiple niches for hematopoietic stem cell regulations. Stem Cells. 2010; 28(7): 1243-1249.

[2] ScaddenDT. The stem-cell niche as an entity of action. Nature. 2006; 441(7097): 1075-1079.

[3] MorrisonSJ, Scadden DT. The bone marrow niche for haematopoietic stem cells. Nature. 2014; 505(7483): 327-334.

[4] ComazzettoS, ShenB, MorrisonSJ. Niches that regulate stem cells and hematopoiesis in adult bone marrow. Dev Cell. 2021; 56(13): 1848-1860.

[5] ShortNJ, Rytting ME, CortesJE. Acute myeloid leukaemia. Lancet. 2018; 392(10147): 593-606.

[6] DiNardoCD, ErbaHP, FreemanSD, Wei AH. Acute myeloid leukaemia. Lancet. 2023; 401(10393): 2073-2086.

[7] BaryawnoN, Przybylski D, KowalczykMS, et al. A cellular taxonomy of the bone marrow stroma in homeostasis and leukemia. Cell. 2019; 177(7): 1915-1932 e16.

[8] DoanPL, ChuteJP. The vascular niche: home for normal and malignant hematopoietic stem cells. Leukemia. 2012; 26(1): 54-62.

[9] CarrollD, St Clair DK. Hematopoietic stem cells: normal versus malignant. Antioxid Redox Signal. 2018; 29(16): 1612-1632.

[10] LongNA, GollaU, SharmaA, Claxton DF. Acute myeloid leukemia stem cells: origin, characteristics, and clinical implications. Stem Cell Rev Rep. 2022; 18(4): 1211-1226.

[11] NewellLF, CookRJ. Advances in acute myeloid leukemia. BMJ. 2021; 375: n2026.

[12] BhansaliRS, PratzKW, LaiC. Recent advances in targeted therapies in acute myeloid leukemia. J Hematol Oncol. 2023; 16(1): 29.

[13] KaraN, XueY, ZhaoZ, et al. Endothelial and Leptin Receptor(+) cells promote the maintenance of stem cells and hematopoiesis in early postnatal murine bone marrow. Dev Cell. 2023; 58(5): 348-360 e6.

[14] ShiMM, KongY, SongY, et al. Atorvastatin enhances endothelial cell function in posttransplant poor graft function. Blood. 2016; 128(25): 2988-2999.

[15] KongY, ShiMM, ZhangYY, et al. N-acetyl-L-cysteine improves bone marrow endothelial progenitor cells in prolonged isolated thrombocytopenia patients post allogeneic hematopoietic stem cell transplantation. Am J Hematol. 2018; 93(7): 931-942.

[16] TangSQ, XingT, LyuZS, et al. Repair of dysfunctional bone marrow endothelial cells alleviates aplastic anemia. Sci China Life Sci. 2023; 66(11): 2553-2570.

[17] KongY, SongY, TangFF, et al. N-acetyl-L-cysteine improves mesenchymal stem cell function in prolonged isolated thrombocytopenia post-allotransplant. Br J Haematol. 2018; 180(6): 863-878.

[18] KongY, WangY, ZhangYY, et al. Prophylactic oral NAC reduced poor hematopoietic reconstitution by improving endothelial cells after haploidentical transplantation. Blood Adv. 2019; 3(8): 1303-1317.

[19] LiangM, LyuZS, ZhangYY, et al. Activation of PPARdelta in bone marrow endothelial progenitor cells improves their hematopoiesis-supporting ability after myelosuppressive injury. Cancer Lett. 2024; 592: 216937.

[20] WenQ, XuZL, WangY, et al. Glucocorticoid and glycolysis inhibitors cooperatively abrogate acute graft-versus-host disease. Sci China Life Sci. 2023; 66(3): 528-544.

[21] LyuZS, TangSQ, XingT, et al. The glycolytic enzyme PFKFB3 determines bone marrow endothelial progenitor cell damage after chemotherapy and irradiation. Haematologica. 2022; 107(10): 2365-2380.

[22] XingT, HuLJ, ZhaoHY, et al. Bone marrow endothelial progenitor cells remodelling facilitates normal hematopoiesis during acute myeloid leukemia complete remission. Nat Commun. 2024; 15(1): 10832.

[23] WangZK, ZhangZW, LyuZS, et al. Inhibition of TGF-beta signaling in bone marrow endothelial cells promotes hematopoietic recovery in acute myeloid leukemia patients. Cancer Lett. 2024; 605: 217290.

[24] ShirotaT, Tavassoli M. Cyclophosphamide-induced alterations of bone marrow endothelium: implications in homing of marrow cells after transplantation. Exp Hematol. 1991; 19(5): 369-373.

[25] KoppHG, Avecilla ST, HooperAT, et al. Tie2 activation contributes to hemangiogenic regeneration after myelosuppression. Blood. 2005; 106(2): 505-513.

[26] MartinezJR, DhawanA, Farach-CarsonMC. Modular proteoglycan Perlecan/HSPG2: mutations, phenotypes, and functions. Genes. 2018; 9(11): 556.

[27] AviezerD, HechtD, SafranM, Eisinger M, DavidG, YayonA. Perlecan, basal lamina proteoglycan, promotes basic fibroblast growth factor-receptor binding, mitogenesis, and angiogenesis. Cell. 1994; 79(6): 1005-1013.

[28] BrownJC, SasakiT, GohringW, Yamada Y, TimplR. The C-terminal domain V of perlecan promotes beta1 integrin-mediated cell adhesion, binds heparin, nidogen and fibulin-2 and can be modified by glycosaminoglycans. Eur J Biochem. 1997; 250(1): 39-46.

[29] SadatsukiR, KanekoH, KinoshitaM, et al. Perlecan is required for the chondrogenic differentiation of synovial mesenchymal cells through regulation of Sox9 gene expression. J Orthop Res. 2017; 35(4): 837-846.

[30] IshijimaM, SuzukiN, HozumiK, et al. Perlecan modulates VEGF signaling and is essential for vascularization in endochondral bone formation. Matrix Biol. 2012; 31(4): 234-245.

[31] GrigorianM, LiuT, BanerjeeU, Hartenstein V. The proteoglycan Trol controls the architecture of the extracellular matrix and balances proliferation and differentiation of blood progenitors in the Drosophila lymph gland. Dev Biol. 2013; 384(2): 301-312.

[32] KongY, CaoXN, ZhangXH, et al. Atorvastatin enhances bone marrow endothelial cell function in corticosteroid-resistant immune thrombocytopenia patients. Blood. 2018; 131(11): 1219-1233.

[33] XingT, LyuZS, DuanCW, et al. Dysfunctional bone marrow endothelial progenitor cells are involved in patients with myelodysplastic syndromes. J Transl Med. 2022; 20(1): 144.

[34] LyuZS, CaoXN, WenQ, et al. Autophagy in endothelial cells regulates their haematopoiesis-supporting ability. EBioMedicine. 2020; 53: 102677.

[35] TakanoF, TanakaT, AoiJ, YahagiN, FushiyaS. Protective effect of (+)-catechin against 5-fluorouracil-induced myelosuppression in mice. Toxicology. 2004; 201(1-3): 133-142.

[36] HeM, WangN, ZhengW, et al. Ameliorative effects of ginsenosides on myelosuppression induced by chemotherapy or radiotherapy. J Ethnopharmacol. 2021; 268: 113581.

[37] ZhouX, VovkEI, LiuY, GuanC, YangY. An in situ temperature-dependent study of La(2)O(3) reactivation process. Front Chem. 2021; 9: 694559.

[38] HooperAT, ButlerJM, NolanDJ, et al. Engraftment and reconstitution of hematopoiesis is dependent on VEGFR2-mediated regeneration of sinusoidal endothelial cells. Cell Stem Cell. 2009; 4(3): 263-274.

[39] DeCarloAA, Whitelock JM. The role of heparan sulfate and perlecan in bone-regenerative procedures. J Dent Res. 2006; 85(2): 122-132.

[40] ZoellerJJ, Whitelock JM, IozzoRV. Perlecan regulates developmental angiogenesis by modulating the VEGF–VEGFR2 axis. Matrix Biol. 2009; 28(5): 284-291.

[41] HayesAJ, Farrugia BL, BioseIJ, BixGJ, Melrose J. Perlecan, a multi-functional, cell-instructive, matrix-stabilizing proteoglycan with roles in tissue development has relevance to connective tissue repair and regeneration. Front Cell Dev Biol. 2022; 10: 856261.

[42] HanZ, NiJ, SmitsP, et al. Extracellular matrix protein 1 (ECM1) has angiogenic properties and is expressed by breast tumor cells. FASEB J. 2001; 15(6): 988-994.

[43] NicoliniG, ForiniF, KusmicC, Iervasi G, BalzanS. Angiopoietin 2 signal complexity in cardiovascular disease and cancer. Life Sci. 2019; 239: 117080.

[44] XieJY, WeiJX, LvLH, et al. Angiopoietin-2 induces angiogenesis via exosomes in human hepatocellular carcinoma. Cell Commun Signal. 2020; 18(1): 46.

[45] Eleveld-TrancikovaD, Janssen RA, HendriksIA, et al. The DC-derived protein DC-STAMP influences differentiation of myeloid cells. Leukemia. 2008; 22(2): 455-459.

[46] ParisiS, Battista M, MustoA, NavarraA, Tarantino C, RussoT. A regulatory loop involving Dies1 and miR-125a controls BMP4 signaling in mouse embryonic stem cells. FASEB J. 2012; 26(10): 3957-3968.

[47] GrindelBJ, Martinez JR, PenningtonCL, et al. Matrilysin/matrix metalloproteinase-7(MMP7) cleavage of perlecan/HSPG2 creates a molecular switch to alter prostate cancer cell behavior. Matrix Biol. 2014; 36: 64-76.

[48] ZhangW, LinZ, ShiF, et al. HSPG2 mutation association with immune checkpoint inhibitor outcome in melanoma and non-small cell lung cancer. Cancers. 2022; 14(14): 3495.

[49] ZhouX, LiangS, ZhanQ, Yang L, ChiJ, WangL. HSPG2 overexpression independently predicts poor survival in patients with acute myeloid leukemia. Cell Death Dis. 2020; 11(6): 492.

RIGHTS & PERMISSIONS

2025 The Author(s). Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.